Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 154.38B |
| Revenue (ttm) | 12.52B |
| Net Income (ttm) | 1.24B |
| Shares Out | 1.73B |
| EPS (ttm) | 0.74 |
| PE Ratio | 120.39 |
| Forward PE | 54.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,496,890 |
| Average Volume | 11,554,643 |
| Open | 90.85 |
| Previous Close | 89.45 |
| Day's Range | 88.40 - 91.45 |
| 52-Week Range | 28.65 - 109.10 |
| Beta | 0.18 |
| RSI | 58.41 |
| Earnings Date | Mar 25, 2026 |
About Innovent Biologics
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injec... [Read more]
Financial Performance
In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.
Financial numbers in CNY Financial StatementsNews
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
SAN FRANCISCO and SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializ...
Innovent Biologics: TABOSUN Receives NMPA Approval
(RTTNews) - Innovent Biologics (IVBXF, 1801.HK) announced that the New Drug Application for TABOSUN has been approved by China's National Medical Products Administration, in combination with sintilima...
China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instabili...
Innovent's Mazdutide Shows Significant Weight Loss & Metabolic Benefits In Chinese Adolescents
(RTTNews) - Innovent Biologics Inc. (IVBXF, 1801.HK) announced that its Phase 1b clinical trial of mazdutide injection (IBI362), a GLP-1 and glucagon dual receptor agonist, in Chinese adolescents with...
Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Innovent's PECONDLE Delivers Durable Efficacy And Safety In Phase 3 Psoriasis Trial
(RTTNews) - Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company, announced that PECONDLE (picankibart injection), its self-developed recombinant anti-interleukin-23p19 subunit ...
ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% ...
Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
SAN FRANCISCO and SUZHOU, China , Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ...
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China , Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...
Innovent, Takeda Close $11.4 Bln Collaboration To Advance Next-Generation IO And ADC Therapies
(RTTNews) - Innovent Biologics (IVBXF, 1801.HK) announced that its global strategic collaboration with Takeda (4502.T, TAK) has officially closed and become effective following the satisfaction of all...
China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval
PECONDLE® (picankibart injection) has received approval from China's National Medical Products Administration (NMPA) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are ...
Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator's Value
SAN FRANCISCO and SUZHOU, China , Nov. 23, 2025 /PRNewswire/ -- Innovent Biologics (Stock Code: 01801.HK), a world-class biopharmaceutical company that develops, manufactures and commercializes high-q...
Innovent, first Chinese firm to market weight-loss drug, joins Hang Seng Index
Innovent Biologics will join the Hang Seng Index next month in the latest quarterly review as the compiler of the city’s stock benchmark presses ahead with its plan to increase the number of constitue...
Innovent Biologics' Mazdutide Phase 3 Trial In Obesity Achieves Primary & Key Secondary Endpoints
(RTTNews) - Innovent Biologics, Inc. (IVBXF, 1801.HK) announced that the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in ...
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
SAN FRANCISCO and SUZHOU, China , Nov. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali...
Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration. The clinical Phase 1 data of IBI301...
Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
SAN FRANCISCO and SUZHOU, China , Nov. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...
Innovent's License Deal Fails To Excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $ 11.4 billion, pocketing a big downpayment, so why did its stock price fall? Key Takeaways: Innovent and it...
China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study
China's Innovent Biologics saidon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients with diabetes than injectable semaglutide, the active ingredient in N...
Innovent Biologics' Mazdutide Surpasses Semaglutide In HbA1c And Weight Loss In Phase 3 Trial
(RTTNews) - Innovent Biologics Inc. (IVBXF, 01801.HK) announced positive results from its fourth Phase 3 clinical trial, DREAMS-3, evaluating mazdutide—a dual GLP-1 and glucagon receptor agonist. The ...
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group DREAMS-3 is the world's firs...
Market Today: Innovent and Takeda's $11.4B Deal Boosts Biotech Sector
Market Today: Innovent and Takeda's $11.4B Deal Boosts Biotech Sector
Innovent Biologics (IVBIY) and Takeda Partner for $11.4 Billion Cancer Therapy Deal
Innovent Biologics (IVBIY) and Takeda Partner for $11.4 Billion Cancer Therapy Deal
Innovent inks $11.4 billion cancer drug partnership with Japan's Takeda
China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion
The tie-up is the latest between Chinese companies and international pharma majors looking to expand their global reach and tap promising drug pipelines developing in China.